OBJECTIVE -Ketosis-prone diabetes (KPD) comprises four subgroups based on the presence or absence of ␤-cell autoantibodies (Aϩ or AϪ) and ␤-cell functional reserve (␤ϩ or ␤Ϫ). Genetic factors could contribute to their distinctive phenotypes. Our aim was to specify the role of HLA class II alleles associated with susceptibility or resistance to autoimmune type 1 diabetes in determining KPD phenotypes.
K
etosis-prone diabetes (KPD), an emerging form of diabetes defined by presentation with diabetic ketoacidosis (DKA) (1) (2) (3) (4) (5) (6) (7) , is phenotypically heterogeneous (1) (2) (3) (4) (5) (6) . KPD patients may have variable ␤-cell function and clinical outcomes after the initial presentation with DKA. Of several methods to define its subgroups, the A␤ scheme (3, 8) , based on presence or absence of autoimmune markers (Aϩ or AϪ) and of ␤-cell functional reserve (␤ϩ or ␤Ϫ), is the most accurate in predicting long-term ␤-cell function and clinical outcomes (8 -10) . Aϩ␤Ϫ and Aϩ␤ϩ KPD patients have autoantibodies against the 65-kDa isoform of GAD (GAD65) or tyrosine-phosphatase-like protein (insulinoma-associated protein-2), while AϪ␤Ϫ and AϪ␤ϩ KPD patients do not. Aϩ␤Ϫ and AϪ␤Ϫ KPD patients lack ␤-cell functional reserve and remain totally insulin dependent, whereas Aϩ␤ϩ and AϪ␤ϩ KPD patients retain ␤-cell functional reserve when assessed repeatedly, with variable long-term insulin dependency (3) . We have previously reported the rationale underlying this classification and nomenclature for KPD (3, 8) ; briefly, they specify important differences in phenotype and natural history that are obscured in the current American Diabetes Association classification scheme, wherein both ␤Ϫ subgroups would be termed type 1 diabetes and both ␤ϩ groups would be termed type 2 diabetes. With the exception of the strong autoimmune basis for ␤-cell functional loss in Aϩ␤Ϫ KPD (11, 12) , the factors underlying irreversible or reversible severe ␤-cell dysfunction in the KPD subgroups remain unclear and may be complex, even for the other subgroup with an apparent autoimmune basis (Aϩ␤ϩ KPD) (13) .
Genetic factors could contribute to the phenotypic differences between KPD subgroups. Here, we investigated whether HLA class II alleles associated with susceptibility or resistance to autoimmune type 1 diabetes (2,6,14 -25) could play a role in specifying the phenotypes. We measured an array of HLA class II alleles at the DQA1, DQB1, and DRB1 loci (including those previously associated with susceptibility or resistance to autoimmune diabetes) in a prospective cohort of KPD patients, analyzed their relationship to the four phenotypes, and compared them with those reported for ethnic-specific normal control populations in Texas by the American Society of Histocompatibility and Immunogenetics (1998) (26 -28) . DKA was defined as described previously by us (3). GAD65 and insulinomaassociated protein-2 autoantibodies were measured in sera as reported previously (29, 30, 31) , using normal ranges established for each ethnic group (3). Patients were classified as ␤ϩ or ␤Ϫ by the presence or absence of ␤-cell functional reserve, as measured within 2 weeks after resolution of initial presentation with DKA and after the 12-month follow-up. The cutoffs and analysis to validate them have been published (3) .
RESEARCH DESIGN AND METHODS
Genotyping for HLA class II alleles associated with susceptibility or resistance to autoimmune type 1 diabetes in previous reports (2,6,14 -25) was performed by an oligoblot method using sequencespecific oligonucleotides on genomic DNA (18) . The polymorphic second exons of DQA1, DQB1, DRB1, DRB3, DRB4, and DRB5 were PCR amplified and labeled by incorporation of digoxigeninlabeled 2Ј-deoxyuridine 3Ј-triphosphate. PCR products were hybridized to allelespecific probes selected from these exons. The blots were detected using antidigoxigenin antibody conjugated to alkaline phosphatase followed by CDP-Star, (chemiluminescent substrate for alkaline phosphatase; Roche Applied Sciences, Indianapolis, IN) and visualized by autoradiography. Long-term insulin dependence was assessed in all patients, and insulin was discontinued in patients initially categorized as ␤ϩ, as previously described (3) .
Homeostasis model assessment (HOMA) of insulin sensitivity and ␤-cell function were measured at baseline and periodically thereafter using the HOMA2 model (32 RESULTS -In this analysis of 185 consecutive KPD patients, frequency distributions of the four KPD subgroups were 18% Aϩ␤Ϫ, 20% AϪ␤Ϫ, 8% Aϩ␤ϩ, and 54% AϪ␤ϩ. Their demographic and clinical characteristics are shown in Table 1 . The mean age at diagnosis of diabetes was significantly higher and the duration of diabetes significantly shorter in the two ␤ϩ groups compared with the two ␤Ϫ groups (P Ͻ 0.0001). There were no significant differences in sex or ethnic distribution across the four groups, though African Americans were highly represented in the Aϩ␤Ϫ group (58%) and Hispanics in the AϪ␤ϩ group (54%). BMI was significantly lower in the two ␤Ϫ groups compared with the ␤ϩ groups (P Ͻ 0.0001).
At baseline, A1C was not significantly different among the four groups. After 12 months of treatment in the dedicated research clinic, A1C was significantly lower in the two ␤ϩ groups than in the two ␤Ϫ groups (P Ͻ 0.0001). HOMA2 of ␤-cell function and HOMA2 of insulin resistance were significantly higher in the ␤ϩ groups than in the two ␤Ϫ groups, both at baseline and at 12 months (P Ͻ 0.0001) ( Table 1) . Insulin was successfully discontinued in 50% (7 of 14) of patients in the Aϩ␤ϩ subgroup and 44% of patients (44 of 100) in the AϪ␤ϩ subgroup, whereas all patients in the Aϩ␤Ϫ and AϪ␤Ϫ groups remained on insulin (P Ͻ 0.0001) after 12 months.
There were significant group differences in HLA class II susceptibility allele frequency (Fig. 1A) due to higher fre- Data are means Ϯ SD or n (%).
quency in the two Aϩ compared with the two AϪ groups (P Ͻ 0.0001). The most significant difference occurred between the two most phenotypically divergent groups, Aϩ␤Ϫ KPD (highest) and AϪ␤ϩ KPD (lowest). The two clinically similar ␤Ϫ groups, Aϩ␤Ϫ KPD and AϪ␤Ϫ KPD, also differed, with a significantly lower frequency of susceptibility alleles in the latter (P ϭ 0.004). Susceptibility allele frequencies were not different between the two Aϩ groups. There were also significant group differences among the resistance alleles (Fig.  1B) , with significantly higher resistance allele frequency in the two AϪ groups collectively than the two Aϩ groups (45% compared with 23%, P ϭ 0.01). The most significant difference occurred between the two most phenotypically divergent groups, Aϩ␤Ϫ KPD (lowest) and AϪ␤ϩ KPD (highest).
Compared with the two ␤Ϫ groups, the two groups with preserved ␤-cell functional reserve had a higher frequency of a resistance allele (48% compared with 25%, P Ͻ 0.01) and a lower frequency of a susceptibility allele (57% compared with 79%, P Ͻ 0.01). ␤ϩ patients had a significantly higher frequency of the autoimmune type 1 diabetes resistance allele DQB1*0602 (18% among ␤ϩ patients compared with 3% among ␤Ϫ patients; P Ͻ 0.01). The frequency of DQB1*0602 was highest in AϪ␤ϩ KPD, with 20% of patients possessing this allele compared with 4% in the other three groups combined (P Ͻ 0.001).
The susceptibility allele DRB1*03 was significantly higher in the two Aϩ groups, and DQB1*02 was significantly higher in the Aϩ␤Ϫ KPD group, than in a large control population sample of the same ethnicities in Texas (Table 2) . However, the frequencies of these alleles were not different between the two AϪ groups and the control subjects. The frequencies of the resistance alleles DRB1*15, DQB1*0301, and DQB1*0303 were significantly lower in the two ␤Ϫ groups than among control subjects; the frequencies of these two DQB1*03 alleles were also lower in the AϪ␤ϩ group. DQB1*0302, a susceptibility allele, had a significantly higher prevalence in the two ␤Ϫ groups and also in the AϪ␤ϩ KPD group.
Since ethnicity affects HLA allele prevalence, we compared frequencies in the Aϩ (Table 3 ) and AϪ (Table 3) KPD groups to ethnic-matched population control subjects. Among the Aϩ KPD groups, frequencies of the susceptibility alleles were generally higher for all ethnicities compared with ethnic-specific control subjects (Table 3 ). DRB1*03 was significantly higher in Hispanic Aϩ KPD patients compared with Hispanic control subjects, and DRB1*04 was significantly higher in African-American Aϩ␤Ϫ KPD patients compared with AfricanAmerican control subjects. DQB1*0302 was higher in Caucasian and AfricanAmerican Aϩ␤Ϫ KPD patients, with a trend toward higher prevalence in Hispanic Aϩ␤Ϫ and in Caucasian Aϩ␤ϩ KPD patients, compared with their respective ethnic control subjects. DQB1*02 was also more frequent in the Aϩ KPD groups compared with ethnicspecific control subjects, although statistical significance was not achieved in some comparisons due to small patient s a m p l e s i z e s . D Q B 1 * 0 3 0 1 a n d DQB1*0303 were significantly less frequent in Hispanic Aϩ␤Ϫ KPD patients than in Hispanic control subjects. Among AϪ KPD groups, frequency of the susceptibility allele DQB1*02 was significantly higher in African-American subjects than in control subjects of the same ethnic group. The frequency of the resistance allele DQB1*0602 was significantly higher in African-American AϪ␤ϩ KPD patients than in African-American control subjects (Table 3 ). The resistance alleles DQB1*0301 and DQB1*0303 were significantly less frequent in Hispanics with AϪ␤Ϫ and AϪ␤ϩ KPD and African Americans with AϪ␤ϩ KPD than among their respective ethnic control subjects. The control allele DQB1*05 was significantly higher in African Americans with AϪ␤Ϫ KPD, and DQB1*06 was significantly lower in Hispanics with AϪ␤ϩ KPD, compared with ethnic-specific control subjects.
CONCLUSIONS -These results demonstrate that HLA class II alleles specify and further define the four subgroups of KPD and suggest that particular genotypes may contribute to distinct KPD phenotypes. There is a high prevalence of susceptibility alleles in the two Aϩ KPD subgroups. This differentiates the two sets of clinically and phenotypically similar groups: Aϩ␤Ϫ from AϪ␤Ϫ KPD patients and Aϩ␤ϩ from AϪ␤ϩ KPD patients (3). The ability of susceptibility allele frequency to distinguish Aϩ␤Ϫ from AϪ␤Ϫ KPD is important for taxonomy and pathophysiology, as it diminishes the likelihood that AϪ␤Ϫ KPD patients have been misclassified due to loss of circulating autoantibodies (33) . The two ␤ϩ KPD groups (late onset and often insulin independent) also have a higher prevalence of resistance alleles and a lower prevalence of susceptibility alleles than the two ␤Ϫ groups (early onset and absolutely insulin dependent).
Previous investigators have described HLA allele associations with KPD. Banerji et al. (2) reported a higher frequency of HLA DR3/DR4 in GAD65 autoantibodynegative African-American patients with type 2 diabetes (65%) compared with nondiabetic control subjects (30%). Umpierrez et al. (6) reported that all those with GAD autoantibodies in a cohort of predominantly African-American KPD patients possessed the DQB1*0201 allele. Wang et al. (34) found that the frequency of the autoimmune type 1 diabetes susceptibility genotype DR3-DQ2/ DR4-DQ8 was 10-fold higher and that of the protective allele DQB1*0602 10-fold lower among newly diagnosed younger children with autoantibodies. Our data suggest that HLA class II alleles also modulate age at presentation and severity of ␤-cell functional loss in KPD patients. DQB1*0602 is associated with dominant protection from diabetes among autoantibody-positive first-degree relatives of patients with autoimmune type 1 diabetes (20, 25, (35) (36) (37) (38) . DQB1*0602 is also significantly more frequent in ␤ϩ than in ␤Ϫ KPD patients. A total of 45-50% of patients in the ␤ϩ KPD groups became insulin independent over time, suggesting a possible effect of this allele in protecting ␤-cell function.
Other findings suggest potential roles for HLA class II alleles in the pathophysiology of ␤-cell dysfunction in autoantibody-negative forms of KPD. For example, African-American AϪ␤ϩ KPD patients had a significantly higher prevalence of the protective allele DQB1*0602 and the susceptibility allele DQB1*02 than AfricanAmerican control subjects. Higher frequencies of some susceptibility alleles in AϪ␤ϩ KPD patients of ethnic minority groups may contribute to their predisposition to develop ␤-cell dysfunction severe enough to develop DKA, while concomitant inheritance of resistance alleles at a higher frequency than in ␤Ϫ KPD subgroups may contribute to their propensity to recover ␤-cell function substantially following an episode of DKA.
Tuomi et al. (39) found that patients with latent autoimmune diabetes of adults, who are GAD antibody positive with a phenotype of type 2 diabetes, have a higher frequency of HLA-DQB1*0302-containing alleles than GAD antibodynegative type 2 diabetic patients and nondiabetic control subjects but a lower frequency than type 1 diabetic patients. Latent autoimmune diabetes of adults patients also had lower fasting C-peptide concentrations and diminished insulin responses to glucose than GAD antibodynegative type 2 diabetic patients. These latent autoimmune diabetes of adults patients would resemble Aϩ␤ϩ KPD, albeit without presentation with DKA. We found that the frequency of DQB1*0302 (and of another susceptibility allele DQB1*02) were higher in all KPD subgroups compared with population control subjects. These loci may contribute to the severe ␤-cell dysfunction resulting in ketoacidosis that defines all forms of KPD. Such a genetic background could contribute to a distinct pathophysiologic process in AϪ␤ϩ KPD patients compared with nonketosis-prone patients with typical type 2 diabetes, such that ␤-cell dysfunction in the former is unmasked more abruptly by the development of insulin resistance.
In conclusion, HLA class II alleles associated with susceptibility or resistance to autoimmune type 1 diabetes further define the four KPD phenotypes. These alleles may also play a role in pathophysiology, as there is a significantly higher prevalence of susceptibility alleles in the autoantibody-positive groups as well as a higher prevalence of resistance alleles in the groups with preserved ␤-cell functional reserve and later onset of diabetes. Inheritance of specific alleles may serve as a marker of the evolution of ␤-cell function and clinical outcomes among KPD patients and identify appropriate candidates for immunomodulatory therapy. Although routine analysis of HLA alleles in KPD patients is not recommended at this time, these associations set the stage for identification of genetic mutations contributing to severe ␤-cell dysfunction in KPD.
